来自HBF的乙肝试验药物，手机复制

春景

        FDA Approved
2006
Viread
(Tenofovir)        Inhibits viral DNA polymerase        Gilead Sciences,
Foster City, CA        FDA Approved 2008
Clevudine
(L-FMAU)
Inhibits viral DNA polymerase        Bukwang,
South Korea
Eisai, Japan        Approved S. Korea
2006 (Levovir)
Tenofovir alafenamide (TAF)
Prodrug of Tenofovir        Gilead Sciences,
Foster City, CA        Phase III
CMX157        Prodrug of Tenofovir        ContraVir Pharmaceuticals,
Edison, NJ        Phase II
AGX-1009        Prodrug of Tenofovir        Agenix, Australia        Phase I, China
Non-Nucleoside Antivirals -  Interfere with proteins involved in viral reproduction
Myrcludex B        Entry Inhibitor        Hepatera, Russia with Myr-GmbH, Germany        Phase II for HBV and HDV
ARC520        RNAi gene silencer        Arrowhead Research, Pasadena, CA        Phase II/III
NVR 3-778        Capsid inhibitor        Novira Therapeutics, Doylestown, PA        Phase IIa
Morphothiadine mesilate (GLS4)        Capsid inhibitor        Sunshine Lake Pharma of HEC, China
Phase II
IONIS-HBVRx (ISIS-HBVRx)        Antisense drug        ISIS Pharma (w/ GSK), Carlsbad, CA
Phase II
SB 9200 HBV        Small molecule nucleic acid hybrids or “SMNH”        Spring Bank Pharma,
Milford, MA
Phase II
Rep 2139-Ca        HBsAg release inhibitor        REPLICor Inc.,
Canada        Phase II
AIC 649 (Bay 41-4109)        Capsid Inhibitor        AiCuris, Germany        Phase I
TKM-HBV        RNAi gene silencer        Tekmira,
Canada
Phase I
IONIS-HBV-LRx (ISIS-GSK6-LRx)        Ligand Conjugated Antisense (LICA) Technology        ISIS Pharma (w/ GSK), Carlsbad, CA        Phase I
Alinia (Nitazoxanide)        Small molecule        Romark Labs,
Tampa, FL        Preclinical
CpAMS        HBV Core Protein        Assembly Biosciences, NY, NY        Preclinical
ALN-HBV        RNAi gene silencer       
Alnylam,
Cambridge, MA

Preclinical
CPI-431-32        Cyclophilin inhibitor       
Ciclofilin Pharma,
San Diego, CA

Preclinical
Hepbarna        RNAi gene silencing       
Benitec, Australia

Preclinical
OCB-030        Cyclophilin inhibitor       
Arbutus Biopharma (formerly Tekmira), Canada

Preclinical
Non-Interferon Immune Enhancers -  Boost T-cell infection-fighting immune cells and natural interferon production
ABX 203        Therapeutic vaccine        ABIVAX,
Paris, France        Phase IIb/III
GS-4774        Therapeutic vaccine        Gilead Sciences with Globe Immune,
Louisville, CO        Phase II
GS-9620        TLR7 agonist        Gilead Sciences,
Foster City, CA        Phase II
RG7795 (formerly ANA773)        TLR7 agonist        Roche, Switzerland        Phase II
CYT107
(Interleukin-7)        Immunomodulator        Cytheris,
France        Phase I/IIa
INO-1800        Therapeutic vaccine        Inovio,
Blue Bell, PA        Phase I
NCT01641536        Therapeutic vaccine        Ichor Medical Systems (w/Janssen), San Diego, CA        Phase I
TG 1050        Immunotherapeutic        Transgene,
Shanghai        Phase I
CYT-003        TLR9 agonist        Arbutus Biopharma (formerly Tekmira), Canada        Preclinical
Hepatitis Delta Virus (HDV) Drug Watch
Myrcludex B        Entry Inhibitor (Targeting NTCP)        Hepatera, Russia with Myr-GmbH, Germany        "Orphan Drug Designation" by US FDA and EMA for HDV
Lonafarnib        Prenylation Inhibitor        Eiger BioPharmaceuticals, Palo Alto, CA        Phase II for HDV
Rep 2139        HBsAg Release Inhibitor         REPLICor, Canada        Phase II for